Pedro Luis Fernandez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6519875/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues. American Journal of Pathology, 2009, 174, 661-670.	1.9	301
2	Galectin-1 Accumulation in the Ovary Carcinoma Peritumoral Stroma Is Induced by Ovary Carcinoma Cells and Affects Both Cancer Cell Proliferation and Adhesion to Laminin-1 and Fibronectin. Laboratory Investigation, 2003, 83, 377-386.	1.7	153
3	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 1270-1284.	1.9	131
4	Activation of nuclear factor-l̂ºB in human prostate carcinogenesis and association to biochemical relapse. British Journal of Cancer, 2005, 93, 1285-1294.	2.9	109
5	18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1551-1557.	3.3	104
6	Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 309-317.	1.4	93
7	Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2012, 11, 329-339.	1.9	92
8	INK4a/ARFLocus Alterations in Human Non-Hodgkin's Lymphomas Mainly Occur in Tumors with Wild-Type p53 Gene. American Journal of Pathology, 2000, 156, 1987-1996.	1.9	83
9	Identification, Characterization, and Intracellular Processing of ADAM-TS12, a Novel Human Disintegrin with a Complex Structural Organization Involving Multiple Thrombospondin-1 Repeats. Journal of Biological Chemistry, 2001, 276, 17932-17940.	1.6	82
10	Differential Expression of cdc25 Cell-Cycle–Activating Phosphatases in Human Colorectal Carcinoma. Laboratory Investigation, 2001, 81, 465-473.	1.7	74
11	Radiologic and Pathologic Findings in Breast Tumors with High Signal Intensity on T2-weighted MR Images. Radiographics, 2010, 30, 533-548.	1.4	73
12	Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Malignant Progression and Drug Resistance in Breast Cancer. Cancer Research, 2013, 73, 6424-6434.	0.4	68
13	Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Annals of the Rheumatic Diseases, 2014, 73, 616-623.	0.5	68
14	CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood, 2002, 100, 4602-4608.	0.6	67
15	MRI of Metaplastic Carcinoma of the Breast. American Journal of Roentgenology, 2005, 184, 1274-1278.	1.0	64
16	Adenoid cystic carcinoma of the breast: mammographic appearance and pathologic correlation American Journal of Roentgenology, 1998, 171, 1679-1683.	1.0	54
17	Cancer Abolishes the Tissue Type-Specific Differences in the Phenotype of Energetic Metabolism. Translational Oncology, 2009, 2, 138-145.	1.7	53
18	PTOV-1, a Novel Protein Overexpressed in Prostate Cancer, Shuttles between the Cytoplasm and the Nucleus and Promotes Entry into the S Phase of the Cell Division Cycle. American Journal of Pathology, 2003, 162, 897-905.	1.9	49

Pedro Luis Fernandez

#	Article	IF	CITATIONS
19	p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene, 1997, 15, 1445-1453.	2.6	45
20	Biobanking: old activity or young discipline?. Seminars in Diagnostic Pathology, 2008, 25, 317-322.	1.0	40
21	The Severe Gout of Holy Roman Emperor Charles V. New England Journal of Medicine, 2006, 355, 516-520.	13.9	36
22	Power Doppler Sonography of Invasive Breast Carcinoma: Does Tumor Vascularization Contribute to Prediction of Axillary Status?. Radiology, 2005, 234, 374-380.	3.6	34
23	Validation Study of a Noninvasive Urine Test for Diagnosis and Prognosis Assessment of Bladder Cancer: Evidence for Improved Models. Journal of Urology, 2014, 191, 261-269.	0.2	30
24	Middleâ€ear adenoma (MEA): a report of two cases, one with predominant â€~plasmacytoid' features. Histopathology, 1997, 30, 359-364.	1.6	28
25	Tumour Banking: The Spanish Design. Pathobiology, 2007, 74, 245-250.	1.9	20
26	Disregulation of p16MTS1/CDK4I protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx. , 1999, 81, 705-711.		19
27	A Practical Approach to Intraoperative Evaluation of Sentinel Lymph Node Biopsy in Breast Carcinoma and Review of the Current Methods. Annals of Surgical Oncology, 2005, 12, 313-321.	0.7	18
28	Patterns of somatic uniparental disomy identify novel tumor suppressor genes in colorectal cancer. Carcinogenesis, 2015, 36, 1103-1110.	1.3	18
29	Metastasis to the nasal cavity from primary rectal adenocarcinoma. Clinical and Translational Oncology, 2009, 11, 117-119.	1.2	14
30	The influence of treatment sequence in the prognostic value of <i>TMPRSS2â€ERG</i> as biomarker of taxane resistance in castrationâ€resistant prostate cancer. International Journal of Cancer, 2019, 145, 1970-1981.	2.3	13
31	A Roman Skeleton with Possible Treponematosis in the Northâ€East of the Iberian Peninsula: A Morphological and Radiological Study. International Journal of Osteoarchaeology, 2013, 23, 651-663.	0.6	12
32	Expression of cyclin D1 and p53 and its correlation with proliferative activity in the spectrum of esophageal carcinomas induced after duodenal content reflux and 2,6-dimethylnitrosomorpholine administration in rats. Carcinogenesis, 2001, 22, 271-277.	1.3	7
33	Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers, 2022, 14, 641.	1.7	7
34	Importance of Intramammary Node Resection in Breast Cancer Staging. Clinical Nuclear Medicine, 2007, 32, 572-573.	0.7	2
35	Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. Scientific Reports, 2022, 12, 8176.	1.6	2